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This study was conducted to determine if oral administration of the novel herbal medicine, MA, and its Lactobacillus acidophilus
fermented product, MA128, have therapeutic properties for the treatment of asthma. Asthma was induced in BALB/c mice by sys-
temicsensitizationtoovalbumin(OVA)followedbyintratracheal,intraperitoneal,andaerosolallergenchallenges.MAandMA128
were orally administered 6 times a week for 4 weeks. At 1 day after the last ovalbumin exposure, airway hyperresponsiveness was
assessed and samples of bronchoalveolar lavage ﬂuid, lung cells, and serum were collected for further analysis. We investigated the
eﬀect of MA and MA128 on airway hyperresponsiveness, pulmonary eosinophilic inﬁltration, various immune cell phenotypes,
Th2 cytokine production, OVA-speciﬁc IgE production, and Th1/Th2 cytokine production in this mouse model of asthma. In
BALB/c mice, we found that MA and MA128 treatment suppressed eosinophil inﬁltration into airways and blood, allergic airway
inﬂammation and AHR by suppressing the production of IL-5, IL-13, IL-17, Eotaxin, and OVA-speciﬁc IgE, by upregulating the
production of OVA-speciﬁc Th1 cytokine (IFN-γ), and by downregulating OVA-speciﬁc Th2 cytokine (IL-4) in the culture super-
natant of spleen cells. The eﬀectiveness of MA was increased by fermentation with Lactobacillus acidophilus.
1.Introduction
Asthma is a chronic, complex respiratory disease caused by
various airway obstructions, airway eosinophilic inﬂamma-
tion, and bronchial hyperresponsiveness [1]. It is a global
health problem that results from a complex interplay bet-
ween genetic and environmental factors [2]a n de x c e s sp r o -
duction of Th2 cytokines (IL-4, IL-5, IL-13) relative to the
Th1 cytokine IFN-γ. Eosinophils have a crucial role in the
pathogenesis of allergic diseases. Clinical and experimental
studies have established eosinophilia as a marked sign of
allergic disorders [3]. IL-4 can directly induce airway hyper-
responsiveness and airway and blood eosinophilia in asth-
matic patients [4], and other investigators have shown an in-
hibitory eﬀect of IFN-γ on pulmonary allergic responses [5].
CD4+ T cells play a crucial role in immune protection
through their capacity to help B cells make antibodies, to re-
cruit neutrophils, eosinophils, and basophils to sites of inﬂa-
mmation, and, through their production of cytokines and
chemokines, to orchestrate immune responses [6]. Suppres-
sion of cytokine production in activated CD4+ Tc ell sm a ybe
useful for the treatment of asthma. Th2 cytokines produced
byCD4+ Tcells,suchasinterleukin-4(IL-4),IL-5,andIL-13,
enhanceimmunoglobulinE(IgE)productionandeosinophil
accumulation, and IL-13 directly enhances mucus hypersec-
retion and AHR [7, 8]. Therefore, suppression of Th2 cyto-
kine production in activated CD4+ Th cells may be useful for
the treatment of inﬂammatory immune diseases including
asthma.
Todevelopanovelherbalmedicinefortreatmentofaller-
gy, MA was prepared with herbs that were traditionally used
to treat diseases related to antiallergy and anti-inﬂammatory.
Recent studies have suggested that fermentation of herbal
extract may have therapeutic advantages due to the increased
absorption and bioavailability of the active components in
the body [9–11]. To increase the antiallergic eﬃcacy of MA,
we fermented it with Lactobacillusacidophilus, whichis natu-
rallyfoundinhumanandanimalGItract,mouth,andvagina2 Evidence-Based Complementary and Alternative Medicine
andismostcommonlyusedasaprobiotic;wethenevaluated
antiasthmatic properties of MA and its fermented product,
MA128, on airway eosinophil accumulation, Th2 cytokine
production, various immune cell phenotypes, and histology
in a murine model of asthma.
2.MaterialsandMethods
2.1. Animals. Five-week-old female BALB/c mice were ob-
tained from Orient Bio Co. Ltd. (Seongnam, Republic of
Korea). The experimental protocols used in the study have
been approved by the committee for animal welfare at Dae-
jeon University. Moreover, all animal procedures were con-
ducted in accordance with the guidelines of the Institution-
al Animal Care and Use Committee of the South Korea Re-
search Institute of Bioscience and Biotechnology (Daejeon,
Republic of Korea).
2.2. Preparation of MA and MA128. All herbal plant mate-
rials were purchased from the Korea Medicine Herbs Asso-
ciation (Yeongcheon, Korea). All voucher specimens were
deposited in the herbal bank of Herbal Medicine Improve-
ment Research Center, Korea Institute of Oriental Medicine.
A mixture of medicinal herbs (1840g) consisting of Sophora
ﬂavescens Aition, Glycyrrhizae Radix, Arctii Fructus, Cnidii
Rhizoma,a n dPolygoni Cuspidati Radix, and so forth, was
boiled in 18.40L of distilled water for 3h using a Herb Ex-
tractor (Kyungseo, Korea), and the extract was ﬁltered using
standard testing sieves (150μm) to yield 15.7L of the decoc-
tion. A 5L portion of the decoction was freeze-dried to give
the dried extract, MA (131.4g), which was stored in desic-
cators at 4◦C until use. For fermentation of MA, a 10L por-
tion of the decoction was adjusted to pH 8.0 using 1M
N a O Ha n dt h e ns t e ri l i z e di na na u t o c l a v ea t1 2 1 ◦C for 5min.
Pure cultures of Lactobacillus acidophilus (KFRI 128) were
obtained from the Korea Food Research Institute (KFRI).
Before experimental use, the bacterial strain was incubated
in MRS medium (10g/L Peptone, 10g/L Beef extract,
5g/LY eastextract,20g/LGlucose,1mL/LT ween80,2g/L
K2HPO4, 5g/L Sodium acetate, 2g/L Triammonium citrate,
0.2g/L MgSO4·7H2O, 0.2 g/L MnSO4·4H2O, pH 6.2–6.6,
Becton Dickinson and Company, Hunt Valley, Md, USA) at
37◦C for 24h. The MA (10L) was inoculated with 10mL of
Lactobacillusacidophilus(1×108 CFU/mL),andfermentedat
37◦C for 48h. The fermented MA was then ﬁltered through
a 60-μm nylon net ﬁlter (Millipore, Billerica, Mass, USA)
and freeze-dried to give the dried fermented extract, MA128
(261.8g), which was stored in desiccators at 4◦C until use.
2.3.HPLCAnalysisofMAandMA128. Theanalyticalperfor-
mance liquid chromatography (HPLC) data were obtained
on an Elite Lachrom analytical HPLC PDA system that
included an L-2130 HPLC pump, an L-2200 autosampler,
column oven (L-2350), and diode array UV/VIS detector
(L-2455). The output signal of the detector was recorded
using EZchrom Elite software for Hitachi. For sample
separation,anOptimaPakC18column(5μm,100 ˚ A,4.6mm
×250mm,RStech,RepublicofKorea)wasused.Themobile
phase was water and acetonitrile containing 1% glacial acetic
acid in a gradient elution at a ﬂow rate of 1.0mL/min and
Table 1: Mobile phase condition of chromatographic separation.
Time (min) Water Acetonitrile Flow rate (mL/min)
09 5 5 1
59 5 5 1
70 0 100 1
80 0 100 1
the column temperature was maintained at 40◦C( T a b l e1).
The injection volume of each sample was 10μL. To prepare
analytical samples, MA and MA128 powders were accurately
weighed and dissolved in 100% H2O at a concentration of
40mg/mL. Prior to analysis, the sample was ﬁltered through
a 0.45-μm ﬁlter.
2.4. Ovalbumin (OVA) Sensitization and Inhalation. As
the modiﬁed protocol previously described [12], OVA
(500μg/mL) in PBS was mixed with equal volumes of 10%
(w/v) aluminum potassium sulfate (alum; Sigma) in distilled
water, then incubated for 60min at RT after adjustment to
pH 6.5 using 10N NaOH, and centrifuged at 750×gf o r5
minutes. The OVA/alum pellet was resuspended to the orig-
inal volume in distilled water. All mice were immunized on
three diﬀerent days (ﬁrst day of 2, 3, 4 weeks before inhala-
tional exposure) by intraperitoneal (I.P.) injections of 0.2mL
alum-precipitatedantigencontaining100μgofO V A(S igma-
A l d r i c hK o r e a ,R e p u b l i co fK o r e a )b o u n dt o4 m go fa l u -
minum hydroxide (Sigma-Aldrich Korea, Republic of Korea)
in PBS. Seven days after the second sensitization by intra-
tracheal injection of 250μg of OVA (on day 21) on the
back of the tongue, mice were exposed to aerosolized
OVA for 30min/day, 3days/week for 5 weeks (at a ﬂow
rate of 250L/min, 1% OVA in normal saline for ﬁrst 4
weeks, and 2% OVA in normal saline for last 1 week). MA
(300mg/kg/day), MA128 (400, 300, 200mg/kg/day), and
cyclosporin A (CsA, 10mg/kg/day) in solution form were
orally administered 3 times a week for the last 5 weeks. One
day after the last OVA exposure (2% OVA inhalation), airway
hyperresponsiveness was determined and samples (broncho-
alveolarlavageﬂuid,lungcells,andserum)werecollectedfor
further molecular analyses.
2.5. Bronchoalveolar Lavage Fluid (BALF). Immediately fol-
lowing assessment of AHR, mice were sacriﬁced by I.P. in-
jection of sodium pentobarbitone (100mgkg−1). The tra-
chea was cannulated and BAL was obtained by washing the
airway lumina. Brieﬂy, cells in the lungs were recovered by
ﬂushing1mLofBALﬂuid(1mMEDTA,10%FBS,PBS)into
the lungs via the trachea. Total cell numbers were counted,
and 100μL of ﬂuid was cytospun onto glass slides using
a Cytospin centrifuge (Cellspin, Hanil, Republic of Korea;
400g for 4 minutes). Diﬀerential cell counts were performed
after staining with a Diﬀ-Quik Stain Set (Baxter Healthcare
Corp., Miami, Fla, USA). The supernatant of BALF was
stored at −25◦C for determination of cytokine levels.
2.6. Digestion of Pulmonary Tissue and Cell Preparations.
Single cell suspensions from lung tissues and BALF wereEvidence-Based Complementary and Alternative Medicine 3
isolated by mechanical disruption in RPMI 1640 medium
supplemented with 2mM L-glutamine, 100U/mL penicillin,
100μg/mL streptomycin, 50μM 2-mercaptoethanol, 20mM
HEPES, and 2% heat-inactivated fetal bovine serum (FBS,
GIBCO, Grand Island, NY, USA). Brieﬂy, the lungs were
removed from thoracic cavity. After mincing using sterile
scalpels,thetissuewasincubatedinPBScontaining1mg/mL
Collagenase IV and 2mg/mL Dispase for 40min at 37◦Ci na
sterile polypropylene tube. After incubation, lung tissue was
vigorously pipetted up and down to further dissolve remain-
ing tissue clumps and then ﬁltered using a 70μm cell strainer
(Falcon, Le Pont de Claix, France). The total number of
cells was counted manually using a hemocytometer chamber
(Fisher). Between 2 and 4 × 103 c e l l sw e r es p u no n t og l a s s
slides (Cytospin centrifuge, Cellspin, Hanil, Republic of
Korea; 400g for 4 minutes). Diﬀerential counts were assessed
according to standard morphologic criteria.
2.7. Determination of Airway Hyperresponsiveness (AHR).
Airway hyperresponsiveness in mice was estimated using a
previously described method with modiﬁcations [13]. A
Buxco system (Biosystem XA; Buxco Electronics Inc, Troy,
Conn, USA) was used to evaluate the extent of airway con-
s t r i c t i o ni nd i ﬀerent groups of mice following the protocol
described previously. Penh is equal to Pause × PEF/PIF,
where Pause = (Te − Tr)/Tr (PIF, peak inspiratory ﬂow;
PEF: peak expiratory ﬂow; Te, expiratory time; Tr, relaxation
time). In this experiment, mice were aerosolized with OVA
for 30min/day, 3days/week for 5 weeks. At 24 hours after the
ﬁnal inhalation, mice were given aerosolized normal saline,
followed by 3.15, 6.25, 12.5, 25, and 50mg/mL methacholine
(Sigma) serially. Airway reactivity was then monitored for
30 minutes. Diﬀerences in Penh value between groups were
evaluated using an unpaired Student’s t-test.
2.8. Hematoxylin-Eosin (H&E), Masson-Trichrome (M-T),
and Periodic Acid-Schiﬀ (PAS) Staining. BALB/c mice were
injected, inhaled, and sprayed with OVA for 5 weeks (three
times a week) to induce asthma. Three experimental groups
were treated with MA (300mg/kg), MA128 (300mg/kg), or
CsA (10mg/kg) for the last 4 weeks (daily). At the end of
the experiment, the lungs were removed and analyzed histo-
logicallyusingamodiﬁedprotocolpreviouslydescribed[14].
Brieﬂy, the lung tissue was embedded in paraﬃn then cut
into 3μm thickness sections for staining with H&E solution
or MT solution. The tissue was subsequently mounted and
coverslipped with Dako-mounting medium (Dakocytoma-
tion; Carpinteria, Calif, USA). The degree of airway inﬂam-
matory cell inﬁltration was scored in a double-blind screen
by two independent researchers. The degree of peribronchi-
ole and perivascular inﬂammation was evaluated on a sub-
jective scale of 0–2 as previously described [15]. Periodic
acid-Schiﬀ (PAS) staining was performed to identify mucus
secretioninlungtissue.Frozensections(30mminthickness)
of each tissue were prepared. Each sample section was
mounted on the gelatin-coated slide, stained with PAS re-
agents, dehydrated, and coverslipped with the permount.
The PAS-positive goblet cells were counted manually and
normalizedtothelengthofthebronchialepithelialperimeter
on the basal side, and expressed as the number of PAS-posi-
tive cells per mm of basement membrane.
2.9. Antibodies and Flow Cytometric Analysis. All antibodies
(such as anti-CD3, CD4, CD8, CCR3, CD69, B220, CD23,
CD11b,andGr-1)forﬂowcytometricanalysiswerepurchas-
ed from Becton Dickinson (BD) PharMingen (San Diego,
Calif, USA). Cells from lung tissues and BALF were stained
with the indicated antibodies in staining buﬀer (PBS con-
taining 1% FBS and 0.01% NaN3) for 10min on ice and ana-
lyzed by two-color ﬂow cytometry on an FACSCalibur using
CellQuest software (BD Biosciences, Mountain View, Calif,
USA).
2.10. Enzyme-Linked Immunosorbent Assay (ELISA). Inter-
leukin (IFN-γ, IL-4, IL-5, IL-13, IL-17, eotaxin, etc.) produc-
tion in BALF and anti-OVA IgE in serum of the indicated
mice (n = 8) was measured by ELISA according to the man-
ufacturer’s instructions with a monoclonal antibody-based
mouse interleukin ELISA kit (R&D system). OVA-speciﬁc
IL-4 and IFN-γ were produced by spleen cells suspended in
RPMI 1640 medium supplemented with 2mM L-glutamine
and 5% fetal bovine serum. The spleen cells were cultured
for 48hrs at a concentration of 1 × 105 cells/well in 96-well
culture plates (Corning Inc., Cambridge, Mass, USA) with or
without 10μg/mL of OVA in a humidiﬁed atmosphere of 5%
CO2 in air at 37◦C. The culture supernatants were collected
and assayed for IFN-γ and IL-4 antibodies induced by OVA
using ELISA. All data represent the mean and standard
deviation from at least three separate determinants and were
compared by analysis of variance (ANOVA).
2.11. Statistical Analysis. Data were analyzed by one-way
analysis of variance (ANOVA) or unpaired Student’s t-test
followed by Dunnett’s multiple comparison test (SPSS ver-
sion 14.0 statistic software). The diﬀerence between the nor-
mal group and the control group (OVA + vehicle) was clearly
distinguished, but statistical signiﬁcance between the normal
group and the control group was not shown in the ﬁgures
andtablestoemphasizethestatisticaldiﬀerencesbetweenthe
experimental groups and the control group. Results (presen-
ted as mean ± standard error of mean) were considered sta-
tistically signiﬁcant if P values were <0.05∗, <0.01∗∗,o r
<0.001∗∗∗.
3. Results
3.1. HPLC Chemical Fingerprinting of MA and MA128. In
this study, an HPLC method was developed to achieve chem-
ical ﬁngerprinting of MA and MA128. Arctiin was used as a
markerstandardasitwasthehighestpeakintheHPLCchro-
matograms of MA and MA128; it was isolated using column
chromatography and identiﬁed using NMR and MS in pre-
liminary study. A binary gradient system consisting of water-
acetonitrile as mobile phase was able to separate the com-
pounds in the extracts and the best wavelength for the detec-
tion was 203nm as it showed the most peaks including the
marker and main peaks (Figure 1). Arctiin (peak 1) appeared
at 28.41min and three other major peaks (peak 2-3) appear-
ed at 33.12, 36.8, and 38.5min, respectively.4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: The HPLC ﬁngerprinting of MA and MA128 at 203nm. (a) Arctiin standard; (b) MA and MA128. 1. Arctiin, tR 28.41min; 2. not
identiﬁed, tR 33.12min; 3. not identiﬁed, tR 36.8min; 4. not identiﬁed, tR 38.5min.
3.2. Inhibitory Eﬀect of MA and MA128 on Airway Hyperre-
sponsiveness(AHR). Inordertoevaluatetheinhibitoryeﬀect
of CsA, MA, and MA128 on airway hyperresponsiveness,
total pulmonary airﬂow in mice was estimated using whole-
body plethysmography. Penh was measured using a Buxco
system on day 1 after ﬁnal inhalation, and samples were im-
mediately collected. Methacholine treatment is useful to de-
monstrate the distinct eﬀect of drugs on Penh value by way
of inducing AHR. In OVA-sensitized/-challenged mice, the
dose-response curve of Penh value was shifted to the left
compared with that of normal mice (Figure 2(b)). As shown
in Figure 2(b), relative to animals sensitized with OVA (con-
trol group), AHR to methacholine was signiﬁcantly reduced
in the MA-treated (300mg/kg) group (P<0.05), MA128-
treated (400, 300 and 200mg/kg) groups (P<0.001, P<
0.01, and P<0.05, resp.), and CsA-treated (10mg/kg) group
(P<0.001). All of the MA128 (400, 300, and 200mg/kg)
groups exhibited dose-dependent inhibitory eﬀects that were
stronger than that of the MA-treated (300mg/kg) group.
3.3. Histological Analysis of Lung Sections. The histopatho-
logical investigation of OVA-challenged mice and MA,
MA128,andCsA-treatedmicerevealedinﬂammatorychang-
es compared with saline-challenged normal mice. Also, we
observed inﬁltration of leukocytes in histologic sections of
lungs from OVA-challenged control mice, and lung tissue
sections from OVA-challenged mice showed a distinct in-
ﬂammatory inﬁltrate and erosion in peribronchial and peri-
vascular areas. The peribronchial and perivascular inﬂam-
matory inﬁltrate consisted of eosinophils and mast cells, ad-
mixed with lymphocytes. Eosinophil inﬁltration was mainly
observed in the peribronchial regions of the lung. In con-
trast, histological sections from MA-treated (300mg/kg)
and MA128-treated (300mg/kg) mice and CsA-treated
(10mg/kg) mice revealed reduced airway inﬂammation in
lung tissue (Figures 3(a) and 3(b)). The degrees of goblet
cell hyperplasia and mucus hyperproduction were evaluated
by means of PAS staining and quantiﬁcation of PAS-stained
cells. The OVA-challenged control mice showed signiﬁcantlyEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀect of MA and MA128 on airway hyperresponsiveness. (a) Schematic diagram of methacholine-induced AHR in the sensitiza-
tion protocol; (b) PenH was measured with a Buxco box, as described in Materials and Methods. Results are expressed as mean ± S.E. (N =
8). Statistical signiﬁcance between control and treatment groups was assessed by ANOVA (∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001). Normal
group:NormalBalb/cmice,OVA-Control:Ovalbumininhalation+vehicle,OVA+CsA(10mg/kg),OVA+MA(300mg/kg),OVA+MA128
(400mg/kg, 300mg/kg, 200mg/kg).
increased mean numbers of PAS-positive cells when com-
pared with saline-challenged normal mice. In particular,
there were greater reductions in the mean number of PAS-
stained goblet cells in the MA and MA128-treated and CsA-
treated asthmatic mice than in OVA-sensitized/-challenged
mice (Figures 3(a) and 3(c)). Therefore, MA128 treatment
showed better lung anti-inﬂammatory eﬃcacy than MA
treatment.
3.4. Inhibitory Eﬀect of MA and MA128 on Airway Eosinophil
Accumulation and Inﬂux of Inﬂammatory Cells into Lung and
BALF. The number of total leukocytes in the BALF obtained
from the PBS saline-challenged group was 3.3 ± 0.25 × 104
cells, indicating that few eosinophils were detected in this
group. On the other hand, the total number of leukocytes
(31.3 ± 2.75 × 104) and eosinophils in the BALF cytospin of
the OVA-challenged was 10 times higher than that in the PBS
saline-challenged group. The total number of leukocytes was
signiﬁcantlyreducedinMAandMA128-treated(300mg/kg)
and CsA-treated mice compared with control mice, and the
number of total lung cells was also signiﬁcantly reduced in
MA and MA128-treated (300mg/kg) and CsA-treated mice
(Figure 4(c)). MA128 (300mg/kg) and CsA (10mg/kg)
also decreased the total number of eosinophils in BALF
(Figure 4(d), and accompanied by changes of eosinophils
counts in BALF (Figure 4(e)).
3.5.InhibitoryEﬀectofMAandMA128onAbsoluteNumberof
Immune Cell Subtypes in Murine OVA-Induced Asthma Lung
and BALF. To evaluate the eﬀect of MA and MA128 on T
and B cell subtypes, ﬂow cytometric analysis was performed.
The numbers of CD4, CD8, CCR3, CD69, B220, CD23,
CD11b, Gr-1 positive cells in the lungs of OVA-challenged
mice were increased compared to those in the saline-treated
group, and generally, each value from MA and MA128-
treated (300mg/kg) and CsA-treated mice were signiﬁcantly
lower than those from OVA-challenged mice (Table 2). Simi-
larly, CsA administration resulted in signiﬁcant reduction in6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Histological analysis of lung sections. (a) Eﬀect of MA and MA128 on histology of lung tissue (H&E, M-T and PAS staining)
in lung cells of the OVA-induced murine model of asthma; (b) total index number of normal to damage (0 to 2); (c) mean number of
PAS-positive cells/mm of bronchiolar basement (PAS staining). H&E: hematoxylin-eosin stain, M-T: Masson trichrome stain, PAS: periodic
acid-Schiﬀ stain, Normal: normal Balb/c mice, OVA-CT: Ovalbumin inhalation + vehicle, OVA + CsA (10mg/kg), OVA + MA (300mg/kg),
OVA + MA128 (300mg/kg). ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001 for control group versus treatment groups.
Tc e l ls u b t y p e s .T h ee ﬀects of MA and MA128 (300mg/kg)
and CsA treatment on leukocyte subsets in lungs and BALF
included marked changes in the numbers of CD4+ helper T
cells, CD8+ c/s T cells, Gr-1+CD11b+ granulocytes, CCR3+
eosinophils,CD4+CD25+ acti vat edTc ells,andB220 +CD23+
B cells in a mouse model of asthma compared to control
group, and the deﬁcits in CCR3+ eosinophils were accom-
panied by concurrent decreases in eosinophils in BALF
cytospin (Figures 4(d) and 4(e)). MA (300mg/kg), MA128
(300mg/kg), and CsA treatment with OVA resulted in sig-
niﬁcant reductions in CD4+ helper T cells (∗∗∗P<0.001),
CD8+ c/sTc ells( ∗∗∗P<0.001), Gr-1+CD11b+ granulocytes
(∗∗∗P<0.001), CD4+CD25+-activated T cells (∗∗P<0.01,
∗∗∗P<0.001), B220+CD23+ B cells (∗∗P<0.01, ∗∗∗P<
0.001),CD4+ helperTcells(∗∗∗P<0.01, ∗∗∗P<0.001),Gr-
1+CD11b+ granulocytes, CCR3+ eosinophils (∗∗∗P<0.01,
∗∗∗P<0.001), CD4+CD25+-activated T cells (∗P<0.05,
∗∗P<0.01), and B220+CD23+ B cells (∗∗∗P<0.001) in
BALF were also decreased signiﬁcantly (Table 2).
Absolute numbers of various immune cell subtypes in
lung and BALF were counted (described in Section 2).
Results are expressed as mean ± S.E. (N = 8). StatisticalEvidence-Based Complementary and Alternative Medicine 7
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Table 2: Quantiﬁcation by FACS analysis of various immune cell subtypes in lung and BALF.
Cell phenotypes in lung &
BAL
Normal OVA-induced asthma mice (total absolute no.)
Balb/c mice Control CsA (10mg/kg) MA (300mg/kg) MA128 (300mg/kg)
Lung
CD4+ (× 106 cells) 1.0 ±0.12 7.0 ±0.17 2.3 ±0.34∗∗∗ 4.0 ±0.31∗∗∗ 3.4 ±0.61∗∗∗
CD8+ (× 106 cells) 1.1 ±0.18 6.7 ±0.60 1.2 ±0.07∗∗∗ 3.8 ±0.18∗∗∗ 2.8 ±0.42∗∗∗
CD4+ CD25+ (× 106 cells) 1.3 ±0.15 11.5±0.12 3.6 ±0.06∗∗∗ 7.1 ±1.09∗∗ 5.5 ±0.61∗∗∗
B220+ CD23+ (× 106 cells) 0.4 ±0.09 4.9 ±0.59 2.0 ±0.26∗∗∗ 3.1 ±0.01∗∗ 2.4 ±0.25∗∗
CD11b+ Gr-1+ (× 106 cells) 0.5 ±0.05 7.7 ±0.31 1.9 ±0.17∗∗∗ 4.0 ±0.20∗∗∗ 3.1 ±0.38∗∗∗
BAL
CD4+ (× 104 cells) 0.8 ±0.01 13.5±1.03 4.6 ±0.50∗∗∗ 9.6 ±0.15∗∗ 6.8 ±1.31∗∗∗
CCR3+ (× 104 cells) 0.1 ±0.05 4.2 ±0.37 1.1 ±0.07∗∗∗ 2.6 ±0.01∗∗∗ 1.9 ±0.47∗∗
CD4+ CD25+ (× 104 cells) 0.4 ±0.06 7.0 ±1.23 2.6 ±0.46∗∗ 4.4 ±0.14∗ 3.9 ±0.91∗
B220+ CD23+ (× 104 cells) 0.1 ±0.02 4.6 ±0.17 1.3 ±0.05∗∗∗ 202 ±0.22∗∗∗ 1.7 ±0.01∗∗∗
signiﬁcance between control and treatment groups was asse-
ssed by ANOVA (∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001).
N: normal Balb/c mice, CT (control): Ovalbumin inhalation
+ vehicle, OVA + CsA (10mg/kg), OVA + MA (300mg/kg),
OVA + MA128 (300mg/kg).
3.6. Inhibition of Th2 Cytokines (In Vivo and Ex Vivo), Eotax-
in, and OVA-Speciﬁc IgE Production in BAL Fluid and Serum.
The eﬀect of MA and MA128 and CsA on Th2 cytokin-
es and eotaxin protein levels was examined in BALF. As
shown in Figures 5(a) and 5(b), IL-5, IL-13, IL-17, and eota-
xin levels were signiﬁcantly reduced in MA128-treated
(300mg/kg) and CsA-treated (10mg/kg) mice. Also, IL-5,
IL-17, and eotaxin levels were signiﬁcantly reduced in MA-
treated (300mg/kg) mice. An important component of the
allergic asthma model is the production of OVA-speciﬁc
IgE. Therefore, levels of anti-OVA IgE were measured in se-
rum from the OVA-challenged, PBS-, MA-, MA128-, and
CsA-treated groups. In our study, OVA-speciﬁc IgE levels in
serum from OVA-induced asthmatic mice were signiﬁcantly
increased compared with those from normal mice (PBS
only), and MA128-treated (300mg/kg) and CsA-treated
(10mg/kg) mice had signiﬁcantly reduced OVA-speciﬁc IgE
(Figure 5(c)). We also measured IL-4 and IFN-γ in the cul-
ture supernatants by ELISA and found that MA128
(300mg/kg) and CsA (10mg/kg) treatments signiﬁcantly in-
hibited Th2 cytokine (IL-4) production in splenocytes
(Figure 5(d)), which was accompanied by a concurrent de-
crease in Th2 cytokine production in BALF (Figure 5(a)).
4. Discussion
Several studies have demonstrated that certain traditional
herbal medicine formulas have therapeutic beneﬁts in aller-
gic asthma [16]. In this murine model for chronic asthma
[17], the changes in airway remodeling were characterized
by epithelial hypertrophy, subepithelial ﬁbrosis, and goblet
cell hyperplasia that developed 4 to 6 weeks after allergen ex-
posure. Many types of inﬂammatory cells, such as mast cells,
eosinophils,andTlymphocytes[18],areinvolvedinthepro-
cess of airway inﬂammation. In addition, various cytokines
and growth factors produced by these cells, such as inter-
leukin (IL)-4, IL-5, IL-10, IL-12, and IL-13, may play im-
portant roles in the disease process [19].
We investigated whether MA and MA128 reduce the ex-
pression of remodeling markers such as goblet cell hyperpla-
sia as well as of proﬁbrogenic mediators in the lung such as
eotaxin, IL-5, and IL-13. IL-5 and eosinophils have recently
been speciﬁcally implicated as key contributors in the devel-
opment of allergic airway inﬂammation. The predominance
of Th2 phenotype of lymphocyte over Th1 phenotype from
a very early stage of life has recently been highlighted, and
this polarization likely has some relationship to the future
development of allergic diseases such as asthma [20].
In our study, MA and MA128 reduced the productions
of Th2 cell-associated cytokines, IL-4 and IL-5, and restored
production of the Th1 cell-associated cytokine, IFN-γ,f r o m
CD4+ T cells prepared from lungs of sensitized mice com-
pared to that in nonsensitized control mice. MA and MA128
also reduced the IL-4 levels and restored the IFN-γ levels
in cultured supernatants from the spleen cells of sensitized
mice. The changes in these cytokine levels in BAL ﬂuid were
no more dramatic than their productions from CD4+ T cells.
It may be that the cytokines detected in BAL ﬂuid originated
from not only lung CD4+ T cells but also from other cells or
serum.
Anti-OVA IgE antibody levels were reduced in the BAL
ﬂuids of the sensitized mice after oral administration of MA
and MA128. It has been reported that Th2 cells encourage
production of IgE antibody [21, 22]. These results indicate
that MA and MA128 have a function that modulates the
proliferation of lung Th cells from Th2-cell-dominant to
Th1-cell-dominant in our murine airway inﬂammation
model.
In our study, MA and MA128 did not reduce the anti-
OVA IgE antibody level in the serum of these sensitized mice.
Therapeuticagentsthatmaybeusedinthetreatmentofasth-
ma are numerous. Anti-IL-5 inhibits eosinophil adhesion,
inﬁltration, and mediator release [23]. Eosinophilia is driven
byallergen-activatedTh2cellsthatgeneratelargeamountsof
Th2cytokines(suchasIL-4,IL-5,andIL-13).IL-5isthemost
critical cytokine mediating increased eosinophil diﬀerentia-
tion, activation, and survival [24]. The recruitment and acti-
vation of eosinophils appear to be controlled by the releaseEvidence-Based Complementary and Alternative Medicine 9
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Figure 5: Cytokines, eotaxin, and ovalbumin-immunoglobulin E production in bronchoalveolar lavage ﬂuid, OVA-speciﬁc splenocytes cul-
ture supernatant, and serum. (a), (b), and (c) Eﬀect of MA and MA128 on Th2 cytokines (IL-5, IL-13), Th1 cytokine (IL-17), eotaxin in
BALF and OVA-speciﬁc IgE in serum; (d) immunomodulatory eﬀects of MA and MA128 on OVA-speciﬁc Th1/Th2 cytokines production in
spleen cells (described in Section 2). Results are expressed the mean ± S.E. (N = 8). Statistical signiﬁcance between control and treatment
groups was assessed by ANOVA (∗P<0.05, ∗∗P<0.01, signiﬁcant increase; ∗P<0.05). Normal: normal Balb/c mice, OVA-CT: Ovalbumin
inhalation + vehicle, OVA + CsA (10mg/kg), OVA + MA (300mg/kg), OVA + MA128 (300mg/kg).
of cytokines such as IL-5 and chemotactic agents such as
eotaxin from Ag-stimulated T lymphocytes [25]. It has been
suggested that IL-5 and eotaxin may collaborate in the regu-
lation of blood and tissue eosinophilia in mice.
The mixture of medicinal herbs known as MA, which
consists of Sophora ﬂavescens Aition, Arctii Fructus, Polygoni
Cuspidati Radix, Lonicera japonica Thunberg, and so forth,
and its fermented product, MA128, has been widely used cli-
nically for the treatment of allergic diseases including bron-
chialasthmaandallergicrhinitis.ThemechanismofMAand
MA128 action in allergic diseases has been studied in vitro
and in vivo. However, its mode of action has not been fully
elucidated for bronchial asthma.
In our preliminary study, MA and MA128 treatment (at
300mg/kg) did not cause toxic eﬀects on alanine amino-
transferase and aspartic acid transaminase levels (data not
shown). Therefore, we used that dose to study their eﬀects in
thismodel.CyclosporinAcanprofoundlyinﬂuencelympho-
cyte activation; it is thus appropriate to consider this drug as
anovelantiasthmatherapy[26].Inourstudy,weusedCsAas
a positive control for immunosuppressants. Recruitment of
eosinophils to the airways is a characteristic of asthma, and
the degree of eosinophilia is correlated with the severity of
the disease. These cells are often considered to play a major
role in inducing airway hyperresponsiveness (AHR) [27].
Eosinophilic inﬂammation is regulated to a major extent by10 Evidence-Based Complementary and Alternative Medicine
activated T lymphocytes in the airways that secrete the Th2
cytokine IL-5 [28]. This cytokine is an important mediator
in the regulation of eosinophilic inﬂammation through its
eﬀects on the proliferation, diﬀerentiation, and activation
of eosinophils and as a signal for the rapid mobilization of
eosinophils from the bone marrow [29].
In our study, MA and MA128 prevented the develop-
ment of AHR, airway eosinophilia, and lung inﬂammation
(Figures 2 and 3), and decreased Th2 cytokine levels in BAL
ﬂuid (Figure 5). These results demonstrate that MA and
MA128haveprofoundregulatoryeﬀectsonthedevelopment
oflungallergicresponsesintheOVA-inducedasthmamodel.
Moreover,theregulatoryeﬀectsexhibitedbyMAandMA128
were accompanied by the production of IL-4 in an in vitro
assay(Figure5(d)).Asthmaproducesimmuneabnormalities
in a wide variety of cell populations. Thus, another goal
in asthma research includes the evaluation of speciﬁc cell
subpopulations. Immunophenotyping by ﬂow cytometry
showed a similar pattern as total lymphocyte numbers in
BALF and lung.
As previously described in the results, the eﬀects of MA
andMA128onleukocytesubsetsinlungsandBALFincluded
marked changes in the numbers of CD4+ helper T cells, Gr-
1+CD11b+ myeloid suppressor cells, CD3−CCR3+ eosino-
phils, CD4+CD25+-activated T cells, and B220+CD23+-
activated B cells in a mouse model of asthma compared to
control group (Table 2), and the deﬁcits in CD3−CCR3+
eosinophils were accompanied by concurrent decreases in
eosinophils in BALF cytospin (Figure 4(d)). MA and MA128
also inhibited B cell-dependent production of OVA-speciﬁc
IgE in serum (Figure 5(c)), which correlated with the result
of B220+CD23+ activated B cells in lung and BALF.
Such CC chemokines as eotaxin and RANTES induce
preferential eosinophil recruitment in allergic inﬂammation.
They also elicit proinﬂammatory eﬀector functions of eosi-
nophils, such as enhanced adhesion and superoxide genera-
tion. Chemokine-induced eosinophil degranulation, a major
eﬀector of eosinophil functions, is mediated through only
CCR3, although some non-CCR3 ligands induce calcium
inﬂux in eosinophils. CCR3 may be an important target in
thetreatmentofeosinophilicinﬂammation[30].Eosinophils
are attracted via their CCR3 to chemoattractants such as
eotaxin released in the airways of asthmatics [31]. Inhibition
of pulmonary eosinophilia by blocking the CCR3 receptor
withantagonistsmayleadtoareductionintheinﬂammation
and the airway responsiveness in asthma. This approach is
being investigated by numerous research groups.
CD11b+Gr-1+, myeloid suppressor cells are referred to
as myeloid-derived suppressor cells and are thought to be a
heterogeneous cellular population containing macrophages,
granulocytes, immature dendritic cells, and early myeloid
precursors. Myeloid suppressor cells constitute a population
of immature myeloid cells with potent immunosuppressive
functions. They can induce immunosuppression under nor-
mal, inﬂammatory, or surgical/traumatic stress conditions
[32]. The increase of Gr-1+CD11b+ myeloid-derived cells in
allergic inﬂammation is related to OVA-induced asthma in
mice [33].
In our study, CD11b+Gr-1+ myeloid suppressor cells
were increased with OVA challenge but signiﬁcantly decreas-
edwithMAandMA128treatment(Table1).Eotaxinwasini-
tially discovered using a biological assay designed to identify
the molecules responsible for allergen-induced eosinophil
accumulation in the lungs of guinea pigs [34]. The speciﬁc
activity of all eotaxins is mediated by the selective expression
oftheeotaxinreceptor,CCR3,aseven-transmembranespan-
ning, G protein-coupled receptor that is primarily expressed
on eosinophils [35], and also noted on a subset of Th2 cells
[36]a n dm a s tc e l l si nh u m a n s[ 37]: CCR3 has been pre-
viously implicated in allergen-induced AHR [38]. However,
the information regarding eotaxin and AHR is complex. In
many cases, eotaxin caused substantial airway eosinophilia
and, in conjunction with IL-5, and IL-13, caused an even
more marked increase in eosinophils [39].
We observed signiﬁcant correlations between eotaxin,
IL-5, and IL-13 levels, and CCR3 expression on eosinophils.
We hypothesize that MA and MA128 and CsA prevent AHR
by downregulating eotaxin, IL-5 and IL-13 expression and,
in so doing, by reducing eosinophilia.
A recent study showed that the excessive production of
interleukin (IL)-4, IL-5, and IL-13 by T-helper type 2 (Th2)
cells is implicated in the development of asthma [40]. IL-5
mobilizes eosinophils from the bone marrow pool and
chemokines such as eotaxin-1 induce the recruitment of
eosinophils into the airway of experimental asthma models
[41].However,theTcelldiversityhasbeenexpandedtoseve-
ral subpopulations, including T helper 17 (Th17) cells, sug-
gesting that the mechanism is more complicated [42]. Inter-
estingly, IL-17 is upregulated in asthma as eosinophils are
cellular sources of its production, and IL-17 increases syn-
thesis of IL-6and IL-11 by bronchial ﬁbroblastsderived from
bronchial biopsies of asthmatic subjects. Several reports have
demonstrated that TH2-type cytokines, including IL-4 and
IL-13, enhance IL-17–induced release of IL-6 from ﬁbrob-
lasts, suggesting that IL-17 might be involved in asthma,
whichis aTH2-mediated disease [43]. Our results of increas-
ed expression of IL-17 in asthmatic samples support the role
of IL-17 in asthma but do not explain its mechanism of
action. To our knowledge, this expression of IL-17 in asth-
matic lungs demonstrates the capacity of eosinophils to pro-
duce this potentially proﬁbrotic cytokine. Therefore, our
result can partly explain the reported inhibition of the Th2
cytokine (IL-5, IL-13), eotaxin, and IL-17 protein levels. A
possible explanation could be that, in each speciﬁc mech-
anism, one or the other population can predominate and
characterize the ﬁnal result.
Therefore, MA and its fermented product, MA128, may
reduce Th2 cytokine (IL-5, IL-13) production and gene ex-
pressionbyinhibitingIL-4expression.Ourresultisnotsuﬃ-
cient to explain the precise mechanism, which is more com-
plicated. However, one possible mechanism is that MA and
M A 1 2 8s h i f t si m m u n i t yf r o maT h 2t oaT h 1b i a si nt h e
murine model of asthma. It would be interesting to precisely
identify the complicated mechanisms of our results concern-
ing Th1/Th2 transcription factors in future studies.
Recently, several studies have reported that certain tradi-
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beneﬁts in allergic murine asthma model [44, 45]. Chung-
Sang-Bo-Ha-Tang (CSBHT) [44] and Sho-seiryu-to (SST,
Xiao-Qing-Long-Tang in Chinese) have been used to treat
chronic asthma in Korea, China, and Japan for centuries
[45]. The previous studies demonstrated that the approved
eﬀective dosages of CSBHT and SST for asthma were
1,000mg/kg/dayand500mg/kg/daywhilethedosagesofMA
and MA128 were 300mg/kg/day. The comparison of the rel-
ative eﬃcacy among these traditional herbal medicines was
complicated due to the diﬀerent sensitivities following the
diﬀerent experimental conditions, but the eﬃcacies of MA
and MA128 were likely to be stronger than those of CSBHT
and SST. This result implies the possibility of using MA and
MA128 for asthma medications.
5. Conclusion
The results of this study indicate that the herbal complex
MA and its fermented product MA128 have antiasthmatic
eﬀectsbysuppressingeosinophilinﬁltrationintoairwaysand
blood, allergic airway inﬂammation, and AHR, which occur-
red by suppressing the production of IL-5, IL-13, IL-17,
Eotaxin, and OVA-speciﬁc IgE; by upregulating the produc-
tion of OVA-speciﬁc Th1 cytokine (IFN-γ); and by down-
regulating OVA-speciﬁc Th2 cytokine (IL-4) in the culture
supernatant of spleen cells. The eﬀectiveness of MA was in-
creasedbyfermentationwithLactobacillusacidophilus,which
suggests that the biological activity of other herbal medicines
might also be increased by fermentation with probiotics.
Further study will elucidate the active bioconversion con-
stituents and optimize the herbal composition and the fer-
mentation process to increase the eﬀectiveness.
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